GlassScriptPhysician profile
Joshua Brady
NPI 1982280400
$9,255.76
in general payments reported to CMS, 2019-2025
27 companies · $3,128 in 2025
The $3,128 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $479 · 2023: $3,241 · 2024: $2,408 · 2025: $3,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,119 · Travel and Lodging: $1,586 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,119.09 |
| Travel and Lodging | $1,585.85 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,245.71 | 2022-2025 | Revolve, Natrelle Saline-Filled Breast Implants |
| Lilly USA, LLC | $843.36 | 2023-2025 | Olumiant, Ebglyss, Taltz |
| Arcutis Biotherapeutics, INC. | $679.06 | 2023-2025 | Zoryve |
| Ucb, INC. | $602.17 | 2024-2025 | Bimzelx |
| Janssen Biotech, INC. | $539.22 | 2024-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $481.36 | 2023-2025 | Spevigo |
| Genzyme Corporation | $452.00 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $406.83 | 2023-2024 | Sotyktu |
| Pfizer INC. | $349.65 | 2022-2025 | |
| Organogenesis INC. | $315.55 | 2023-2025 | Puraply, Affinity |
| Dermavant Sciences, INC. | $286.81 | 2023-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $219.47 | 2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $208.70 | 2022-2025 | Jublia, Siliq, Arazlo |
| Sun Pharmaceutical Industries INC. | $203.08 | 2024-2025 | |
| Kyowa Kirin, INC. | $198.92 | 2022-2024 | Poteligeo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $188.33 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $144.35 | 2024 | Uvadex |
| Galderma Laboratories, L.P. | $139.83 | 2025 | Nemluvio |
| Organon LLC | $123.85 | 2025 | Vtama |
| Biofrontera INC. | $121.63 | 2025 | Ameluz |
| Krystal Biotech INC | $117.32 | 2023 | Vyjuvek |
| Amgen INC. | $110.17 | 2025 | Otezla |
| Incyte Corporation | $100.33 | 2023 | Opzelura |
| Helsinn Therapeutics (U.S.), INC. | $98.44 | 2022 | |
| Hill Dermaceuticals, INC. | $31.34 | 2025 | Tolak |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| Botanix Sb INC | $17.11 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Brady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.